BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35477179)

  • 1. Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma.
    Li M; Yu H; Qi F; Ye Y; Hu D; Cao J; Wang D; Mi L; Wang Z; Ding N; Ping L; Shu S; Zhu J
    Hematol Oncol; 2022 Oct; 40(4):596-608. PubMed ID: 35477179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.
    Vogiatzi F; Heymann J; Müller K; Winterberg D; Drakul A; Rösner T; Lenk L; Heib M; Gehlert CL; Cario G; Schrappe M; Claviez A; Bornhauser B; Bourquin JP; Bomken S; Adam D; Frielitz FS; Maecker-Kolhoff B; Stanulla M; Valerius T; Peipp M; Kellner C; Schewe DM
    Blood Adv; 2022 Aug; 6(16):4847-4858. PubMed ID: 35820018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.
    Ren S; Cai Y; Hu S; Liu J; Zhao Y; Ding M; Chen X; Zhan L; Zhou X; Wang X
    Biochem Pharmacol; 2021 Jun; 188():114576. PubMed ID: 33930347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
    Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
    Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro.
    Murakami S; Suzuki S; Hanamura I; Yoshikawa K; Ueda R; Seto M; Takami A
    Hematol Oncol; 2020 Dec; 38(5):705-714. PubMed ID: 32822067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
    Lee YG; Guruprasad P; Ghilardi G; Pajarillo R; Sauter CT; Patel R; Ballard HJ; Hong SJ; Chun I; Yang N; Amelsberg KV; Cummins KD; Svoboda J; Gill S; Chong EA; North K; Church SE; Fraietta JA; Chang WJ; Lacey SF; Lu XM; Zhang Y; Whig K; Schultz DC; Cherry S; Gerson J; Schuster SJ; Porazzi P; Ruella M
    Cancer Discov; 2022 Oct; 12(10):2372-2391. PubMed ID: 35904479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
    Melchor J; Garcia-Lacarte M; Grijalba SC; Arnaiz-Leché A; Pascual M; Panizo C; Blanco O; Segura V; Novo FJ; Valero JG; Pérez-Galán P; Martinez-Climent JA; Roa S
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36854569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
    Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
    Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
    Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 14. Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
    Russ A; Hua AB; Montfort WR; Rahman B; Riaz IB; Khalid MU; Carew JS; Nawrocki ST; Persky D; Anwer F
    Blood Rev; 2018 Nov; 32(6):480-489. PubMed ID: 29709247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
    Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
    Luo C; Yu T; Young KH; Yu L
    J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
    Scholze H; Stephenson RE; Reynolds R; Shah S; Puri R; Butler SD; Trujillo-Alonso V; Teater MR; van Besien H; Gibbs-Curtis D; Ueno H; Parvin S; Letai A; Mathew S; Singh A; Cesarman E; Melnick A; Giulino-Roth L
    Blood Adv; 2020 Oct; 4(20):5226-5231. PubMed ID: 33104794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
    Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
    Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy.
    Cao A; Yi J; Tang X; Szeto CW; Wu R; Wan B; Fang X; Li S; Wang L; Wang L; Li J; Ye Q; Huang T; Hsu K; Kabbarah O; Zhou H
    Cancer Res Commun; 2022 Nov; 2(11):1404-1417. PubMed ID: 36970051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
    Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
    Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.